Clinical Trial Detail

NCT ID NCT01990209
Title Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors SCRI Development Innovations, LLC
Indications

estrogen-receptor positive breast cancer

breast cancer

progesterone-receptor positive breast cancer

triple-receptor negative breast cancer

Therapies

Orteronel

Age Groups: adult senior

Additional content available in CKB BOOST